QNCX – quince therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia Research
Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting
Quince Therapeutics, Inc. (NASDAQ: QNCX) is now covered by analysts at Maxim Group. They set a "buy" rating and a $6.00 price target on the stock.
Quince Therapeutics, Inc. (NASDAQ: QNCX) was upgraded by analysts at RODMAN&RENSHAW to a "strong-buy" rating.
Form SC 13G/A Quince Therapeutics, Filed by: TANG CAPITAL MANAGEMENT LLC
Form 8-K Quince Therapeutics, For: Nov 12
Form SC 13D Quince Therapeutics, Filed by: Lamond David
Form 10-Q Quince Therapeutics, For: Sep 30
Form 8-K Quince Therapeutics, For: Nov 13
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.